|Bid||1.950 x 1400|
|Ask||2.150 x 2400|
|Day's range||2.050 - 2.150|
|52-week range||1.550 - 5.750|
|PE ratio (TTM)||N/A|
|Earnings date||30 Oct 2017 - 3 Nov 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||4.25|
The Redwood City, California-based company said it had a loss of 28 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. .
AcelRx (ACRX) receives CRL for its opioid painkiller, Dusvia. The FDA has requested resubmission with additional safety data and recommended changes to drug administration.
Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.
Shares of AcelRx Pharmaceuticals Inc. plunged 69% in premarket trade Thursday, after the Food and Drug Administration said it could not approve the new drug application of AcelRx's pain treatment Dsuvia ...
AcelRx Pharmaceuticalssaw its shares rise nearly 20% on the day in anticipation of an FDA approval for AcelRx's pain medication Dsuvia.